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Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over
the past decade. Nevertheless, the majority of patients do not benefit from them. Virotherapy
is a flexible tool that can be used to stimulate and/or recruit different immune populations.
T-cell enabling virotherapy could enhance the efficacy of immune checkpoint inhibitors, even
in tumors resistant to these inhibitors. The T-cell potentiating virotherapy used here consisted
of adenoviruses engineered to express tumor necrosis factor alpha and interleukin-2 in the
tumor microenvironment. To study virus efficacy in checkpoint-inhibitor resistant tumors, we
developed an anti-PD-1 resistant melanoma model in vivo. In resistant tumors, adding
virotherapy to an anti-PD-1 regimen resulted in increased survival (p=0.0009), when
compared to anti-PD-1 monotherapy. Some of the animals receiving virotherapy displayed
complete responses, which did not occur in the immune checkpoint-inhibitor monotherapy
group.When adenoviruses were delivered into resistant tumors, there were signs of increased
CD8 T-cell infiltration and activation, which - together with a reduced presence of M2
macrophages and myeloid-derived suppressor cells - could explain those results. T-cell
enabling virotherapy appeared as a valuable tool to counter resistance to immune checkpoint
inhibitors. The clinical translation of this approach could increase the number of cancer
patients benefiting from immunotherapies.
Keywords: cancer immunotherapy, oncolytic virus, adenovirus, checkpoint inhibitor resistance,
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The discovery of immune checkpoint pathways such as the
CTLA-4 and PD-1 axes, and their subsequent blockade by
inhibiting antibodies (including, but not restricted to, anti-
CTLA-4, anti-PD-1 and anti-PD-L1) has revolutionized the
field of immunotherapy for cancer (1, 2). However, only a
limited number of patients benefit from these therapies. In the
majority of tumor types response rates in unselected populations
are usually between 10%-40% (3, 4). Even in responding patients,
resistance often develops, leading to disease progression. Thus,
there is an obvious room for improvement (5, 6). Some of those
patients seem to be intrinsically refractory to the immune
checkpoint inhibitors (ICIs) while others stop responding after
an initial response (7). Therefore, ICI refractory patients present
a tremendous unmet clinical need.
Studies trying to unveil the cause of resistance to ICIs point to
multiple possibilities including the presence of mutations in
tumors that render them insusceptible to cytotoxic immune
mechanisms (e.g. mutations in PTEN, EGFR, MYC, JAK1/2,
b2M, etc.) (8–10). Others suggest that resistance mechanisms do
not necessarily stem from genetic mutations in the tumor but
may derive from immunosuppressive conditions that hamper
development of antitumor immunity (e.g. T-cell exhaustion,
altered metabolism, expression of alternative inhibitory
receptors, etc.) (11–13). The most likely scenario is that both
explanations can be true for different tumors.
In a different corner of immunotherapy of cancer are oncolytic
viruses; a tool partially discovered over a hundred years ago.
However, their immunological effects were initially ignored,
resulting in only moderate efficacy results (14). Enthusiasm for
oncolytic viruses was revived with the blooming of immunotherapy
for cancer, as they were found to trigger broad immune responses
that can counter immune suppressive conditions in the tumor
microenvironment (15, 16). Simultaneously, they deliver direct lytic
effects on tumor cells, which helps to reduce tumor burden and
induce antigen release in an immunogenic fashion. However, what
makes them such a versatile tool are the near-infinite possibilities
granted through genetic modification (14, 17, 18). This way, each
virus can be armed to overcome specific efficacy limitations and
hurdles in the tumor microenvironment or to activate different
immune cell types.
An oncolytic adenovirus Ad5/3-E2F-d24-hTNFa-IRES-hIL2
(also known as TILT-123) was engineered for enhanced entry
into tumor cells (19, 20), highly selective tumor replication (21)
and to enable anti-tumor T-cell responses (22–24). The two
cytokines (TNFa and IL-2) were chosen empirically in a data
driven manner as the optimal arming devices in the context of T
cells (22–24). Besides the arming devices encoded by the virus,
the highly immunogenic nature of adenoviruses makes them a
particularly good candidate to engage the T-cell compartment in
tumors (25, 26). This makes them a strong candidate for
boosting T-cell activities such as those needed for the activity
of ICIs.
Clinical studies have shown a positive impact on response
rates against solid tumors when an oncolytic virus was used
together with checkpoint blockade (27, 28). Moreover, we haveFrontiers in Immunology | www.frontiersin.org 2shown pre-clinically that adenoviruses engineered to express
TNFa and IL-2 synergize with checkpoint inhibitors (29) with
promising results. Synergy was mediated by increased trafficking
of anti-tumor immune cells into the tumor niche after
virotherapy. Conversely, ICIs protected effector T cells from
reactive suppressive signals.
In essence, each counterpart of this approach complements
the weakness of the other. Anti-PD-1 therapy requires the
presence of T cells to work, which can achieved by the armed
virus. Any strong immune reaction against the tumor, including
the one mediated by the virus, causes a compensatory immune
suppressive counter-reaction, neutralized by the anti-PD-1 in
this setting.
To study if the use of virotherapy could be a valid approach in
ICI-resistant patients, which currently present tremendous
unmet clinical need, we developed an in vivo model refractory
to anti-PD-1. We then applied treatment with cytokine-armed
adenoviruses, with or without anti-PD-1. The aim of the study
was to evaluate whether the use of virotherapy could yield
therapeutic benefit in ICI resistant conditions.MATERIALS AND METHODS
In Vivo Experiments
In vivo experiments were carried out in C57BL/6OlaHsd female
mice, 4-6 week old by the initiation of the tests (purchased from
Envigo Labs, Huntingdon, UK). 2.5 x 105 B16.OVA melanoma
cells were implanted subcutaneously in the left lower flank.
When the minimum tumor size criterion of 4 mm was met,
animals were randomized into different treatment groups.
Tumor volumes were measured and overall health was assessed
daily. Animals having open wounds (i.e. ulcers at the injection
site) were euthanized. Maximum allowed tumor diameter was
18 mm, after which animals were immediately euthanized.
Animals with no observable tumors were kept alive at least 90
days after they received the first treatment to ensure no
tumor recurrence.
Antibodies and Viruses
Treatment diagrams are provided for each specific experiment.
APD-1 treatments consisted of systemically (intraperitoneally)
delivered antibody dosed as 0.1 mg (clone 10F.9G2, BE0101,
BioXCell, Lebanon, New Hampshire, USA) diluted in PBS.
Virotherapy treatments consisted of 1 x 108 viral particles
(including equal amounts of Ad5-CMV-mIL2 and Ad5-CMV-
mTNFa viruses, non-replicative in mice but historically used as
model for the Ad5 man-based therapies which are replication
competent in that host). The expression of TNFa and IL-2 after
the use of the viruses in B16.OVA model has been studied before
(23). In those experiments including intratumoral virus
treatments, control groups not receiving viruses were injected
intratumorally with an equivalent amount of PBS.
Transcriptome Analyses
Tumors harvested from in vivo experiments were stabilized in
RNAlater (R0901, Sigma-Aldrich, St. Louis, Missouri, USA) andJuly 2021 | Volume 12 | Article 706517
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Germany) kit manufacturer’s guide, RNA was purified from
the tumor samples and the concentration was adjusted based on
the amount of RNA detected with a spectrophotometer
(Biophotometer, Eppendorf, Wesbury, New York, USA).
Sequencing of the RNA samples was outsourced to BGI Tech
Solutions (Tai Po, Hong Kong) that also performed data cleaning
and quantitative analyses in a single blind manner.
CyTOF
Tumors harvested from in vivo experiments were processed into
single cell suspensions and stored in freezing media (including
10% dimethyl sulfoxide) until they were stained for mass
cytometry analyses. The samples were thawed, and stained
with 5uM cisplatin as a viability marker. The cells were fixed
with 1.6% PFA (v/v) in PBS. Samples were barcoded with 20
unique palladium isotopes as per manufacturer’s protocol
(Fluidigm). Samples were treated with Human TruStain FcX
(Biolegend), and antibodies for cell surface staining were added
first, followed by intracellular staining for nuclear and phospho-
proteins. DNA was stained with 1:4000 iridium and fix-perm
buffer (Fluidim) and stored overnight. Samples were acquired the
following day on CyTOF3-Helios mass cytometer in double-
distilled H2O spiked with 10% EQ four element Calibration
Beads (Fluidigm) at a rate of 250-300 events per second. After
acquisition sample files were normalized over time with the use
of the calibration beads and deconvoluted into individual sample
files through Fluidigm debarcoding software. A complete list of
the metal-bound antibodies can be found as Supplementary
Table 1.Frontiers in Immunology | www.frontiersin.org 3Statistical Analyses
GraphPad Prism 8 (GraphPad Software, San Diego, California,
USA) analysis tools were used to perform the log rank Mantel-
Cox test on Kaplan-Meier survival curves and Mann-Whitney
test, as well as a means to generate graphical representations of
the data. SPSS Statistics 25 (IBM, Armonk, New York, USA) was
the software used for analyses on tumor growth evolution based
on daily measures of the tumor diameters with a mixed model
test as described before (29). Statistical significance was set for
p-values under 0.05.RESULTS
B16.OVA Tumor Model Responds to Anti-
PD-1 but Long-Term Efficacy Is Rare
To study the mechanism of resistance to aPD-1, B16.OVA,
a model that displays limited response to PD-1 blocking
antibodies (29, 30), was selected. Animals whose tumor
reached at least 4 mm maximum diameter were randomly
assigned to either “Mock” or “aPD-1” groups. Animals in the
“aPD-1” group received PD-1 inhibiting antibody treatment
systemically once every three days for at least 5 rounds. All
the animals’ tumors were measured daily until the maximum
diameter was at least 10 mm. Animals with tumors surpassing
that threshold were euthanized and tumors collected for further
analysis (Figure 1A).
While the size of tumors at the start of the treatment
period and at the time of euthanasia were the same for bothA
B C
FIGURE 1 | Development of an in vivo model refractory to aPD-1. (A) Experimental design: 17 mice were engrafted with subcutaneous B16.OVA tumors (2.5 x 105
cells/animal). When those tumors reached 4 mm in maximum diameter, the animals were assigned to Mock (n=7) or to aPD-1 group (n=10). 0.1 mg of aPD-1
(or PBS) was given intraperitoneally every three days. When tumors progressed over 10 mm, animals were sacrificed. (B) Percentage of animals with a tumor under
10 mm after they started treatment. (C) Individual tumor growth curves for both groups. (Kaplan-Meier, Log rank Mantel-Cox test; ***p < 0.001, ****p < 0.0001).July 2021 | Volume 12 | Article 706517
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reach the 10 mm diameter threshold was significantly different
in the two groups (p=0.0008) (Figure 1B). Whereas tumors
from the “Mock” group took 5-22 days to reach the maximum
allowed volume, for the “aPD-1” group this was 13-41 days,
with the exception of one complete responder. Thus, aPD-1
treatment showed significant (p=0.0002) benefit in tumor growth
control, and one out of the ten treated animals displayed an
apparent complete response by day 30. Even though the
treatment slowed tumor progression, 90% of the tumors
eventually relapsed and reached the diameter threshold of
10 mm (Figure 1C).
These results show initial tumor growth control upon PD-1
blockade, but also the lack of long-term responses in most
patients, similarly to what is seen with human patients with
single agent ICI.Frontiers in Immunology | www.frontiersin.org 4Tumors That Grow Following Anti-PD-1
Blockade Show Different Gene Expression
Profiles Than Growing Tumors Naïve to
the Therapy
After collection of samples as described in Figure 1A, RNA was
extracted for total RNA sequencing and gene expression
quantification. For this analysis, four samples belonging to the
“Mock” group and six samples from “aPD-1” group were randomly
selected. After data cleaning, samples were arranged in a heatmap
(Figure 2A) and clustered based on similarities between samples.
This approach grouped samples from both groups apart with
reasonable accuracy. The comparison of the expression profiles
between groups identified 357 upregulated or downregulated genes
in tumors treated with aPD-1 (Figure 2B). Out of those genes
(Supplementary Table 2), 19 had a marked connection to the
immune system, based on UniProt annotations (Figure 2C).A B
C
FIGURE 2 | Comparison at the gene expression level of treatment naïve progressing tumors and tumors progressing after aPD-1 therapy. Animals treated as
described in Figure 1A were sacrificed and tumors harvested when they were considered refractory to aPD-1. RNA was extracted and expression profiles from both
groups were compared. (A) Heatmap and unsupervised clustering of samples. (B) Volcano plot for the expression level comparison between treatment naïve and
aPD-1 treated tumors. (C) Immune related significantly regulated genes. (Differences in gene regulations were taken into account if fold change was ≤-2 or ≥2, with a
q-value ≤ 0.001).July 2021 | Volume 12 | Article 706517
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established function, 75% were linked to T cells. Those genes
included T-cell protease precursors (GZMG and GMZF), T-cell
activity regulators (TNFSF18 [a.k.a. GITRL] and EAR2) and
other T-cell proteins relevant in the interaction with other cell
types (KLRC2) and immune components such as the
complement (CD46). Some of the downregulated genes can
also be related to other lymphocyte populations, such as NK
cells or B cells.
Regarding the upregulated genes, most of them were related
to the B-cell compartment (CD19, CD20, CR2, MMP8 and
LY6D), followed by neutrophils (NGP, MMP8 and CXCL3).
Complement-related genes were also noticeable in the
upregulated genes (C1S2 and CR2). In contrast with the high
number of T-cell related genes downregulated in aPD-1
refractory tumors, the only upregulated gene clearly associated
with this cell population was FOXP3, a transcription factor
characteristic of the regulatory T cell population.
Among the whole list of differentially expressed genes
in the aPD-1 refractory tumors, there was an observableFrontiers in Immunology | www.frontiersin.org 5trend indicating suppression of T-cell related genes. Other
cell populations were also affected but the results were not
as clear.
T-Cell Enabling Virotherapy Restores Anti-
PD-1 Responses in Refractory Tumors
Next, we studied whether adenoviruses coding for two cytokines
enhancing anti-tumor T-cell activity (TNFa and IL-2) could
induce responses in the aPD-1 refractory tumors. Similarly as
described in Figure 1A, animals carrying subcutaneous tumors
were treated with aPD-1 (“initial treatment”) until their tumors
progressed and fit the refractory criteria (Figure 3A). After the
refractory status was achieved, animals were randomized into
“aPD-1” group, where animals kept on receiving aPD-1, “Virus”
group, where animals received only virotherapy, or “aPD-1 +
Virus” group, where animals received aPD-1 and additionally
virotherapy (“rescue treatment”). Treatments continued until the
maximum ethically allowed tumor diameter (18 mm) or
apparent complete responses (no visually noticeable lesions in
the original tumor area).A
B
C
FIGURE 3 | The use of an engineered adenovirus is able to trigger tumor growth control in aPD-1 refractory tumors. (A) Experimental design: 29 mice were
engrafted subcutaneously with 2.5 x 105 B16.OVA tumor cells. When those tumors reached 4 mm in maximum diameter, they started receiving 0.1 mg of aPD-1
every three days intraperitoneally. When tumors progressed over 8 mm, animals were assigned to a group where they were treated with the same aPD-1 regimen
(n=8), with 1x108 VP intratumorally once every three days (n=8), or both (n= 8). Treatments continued until complete responses were observed or sacrifice criteria
was reached. (B) Cancer-specific survival. (C) Individual tumor growth curves for the groups. (Kaplan-Meier, Log rank Mantel-Cox test; ***p < 0.001).July 2021 | Volume 12 | Article 706517
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reached the refractory threshold (Figure 3B), When the anti-
PD-1 regimen was combined with T-cell enabling virotherapy,
survival significantly increased (p=0.0009) and even triggered
complete responses in 50% of the animals. Virotherapy alone did
not improve the survival significantly compared to aPD-1 as
monotherapy, but it triggered complete responses in a fraction of
the group. Similar conclusions can be drawn from the analysis of
individual tumor growth curves (Figure 3C). Tumors in the
“aPD-1” group took 6-17 days to go from the refractory
threshold until the maximum ethically allowed tumor volume
while for tumors treated with virotherapy this was 10-32 days,
and it took 13-42 days for tumors receiving both virotherapy and
aPD-1. Within the first 17 days of “rescue treatment” there was a
significant reduction in tumor growth for virotherapy alone
(p=5*10-6) and for virotherapy plus aPD-1 (p=3.44*10-8)
when compared with aPD-1 as monotherapy.
In addition, both survival and tumor growth data serve as a
validation of the previously claimed aPD-1 refractory status, as
the animals in the “aPD-1” group kept on receiving the antibody
but experienced no additional benefit.
Virotherapy Together With Anti-PD-1
Reshapes the Immune Microenvironment
in Anti-PD-1 Refractory Tumors in Favor of
Antitumor Responses
To generate samples to study the immune phenotype of the
tumors, a similar experimental design as in Figure 3A was
followed. However, in this separate experiment, the “rescue
treatment” given after refractory status continued for seven
days (Figure 4A). After that, tumors were collected and
processed for analysis. Tumors were similar in size at baseline
(day 0), when they were determined to be refractory to aPD-1. In
contrast, 7 days later tumors in the “virotherapy alone” group
were smaller (p<0.001). Likewise, tumors in the “virotherapy +
aPD1” group were much smaller than in the “aPD1 alone” group
(p<0.001), and numerically somewhat smaller than in the
“virotherapy alone” group (Figure 4B).
To investigate if co-treatments modify the tumor
microenvironment, day 7 tumors were analyzed by mass
cytometry using 28 cell markers (Supplementary Table 1).
Subsequently, 64 cell clusters were identified among all the
samples by using the FlowSOM algorithm on the CD45+
fraction of the cells. Those clusters were then represented in a
heatmap (Figure 4C) for further elucidation of corresponding
cell types and phenotypes.
Cell clusters resulting from mass cytometry were individually
studied to determine the most likely cell type and phenotype.
Those clusters with the clearest association to a specific cell
population are shown in Figure 5.
Among all 64 cell clusters, 29 had a T-cell phenotype
featuring CD45, CD3ϵ and TCRb co-expression. 22 out of 64
were CD8+ (CD4-) while 4 were CD4+ (CD8-). Additionally,
one cluster (number 4) was CD3e+ TCRb+ CD8+ CD4+ and the
other two (clusters 42 and 43) were CD3e+ TCRb+ CD8- CD4-.
Significant changes in relative frequencies were only observed inFrontiers in Immunology | www.frontiersin.org 6CD8 T-cell clusters but not in CD4, double positive or double
negative T-cell clusters (Figures 5A–H and Supplementary
Figure 2).
Overall, 14 different CD8 T-cell subsets were significantly
increased in tumors when they received both aPD-1 and
virotherapy, as compared to only 5 subsets upon virotherapy
alone. Among these subsets, the combination therapy enhanced
the frequency of T-cells with a phenotype linked to migration to
inflamed sites (based on the CCR2 marker). In addition, these
tumors harbored higher frequencies of effector/memory
proliferative CD8 T cells (based on CD44 and Ki-67 markers),
active and proliferating cells (based on Ki-67 and TIM-3
markers), as well as naïve T-cells (based on CD44 marker).
While the combined use of aPD-1 and virotherapy consistently
led to improved CD8 T-cell infiltration in the tumors,
virotherapy alone did not provide the same degree of efficacy.
In the same vein, the active CD8 by Treg ratio (Figures 5D, H) is
only significantly (p= 0.032) increased when both therapies are
given together.
The main focus in this experiment was to understand better
in lymphoid populations in the tumor but a broad clustering of
relevant myeloid populations was performed (Figures 5I–L).The
levels of M2 macrophages and MDSCs were decreased in the
tumors when virotherapy was added to the treatment. While no
significant changes were observed in M1 macrophages or
dendritic cells for the mentioned combination, remarkably,
dendritic cells were reduced when comparing virotherapy
versus aPD-1 as monotherapies.DISCUSSION
Implementation of ICIs in the therapeutic armamentarium to
fight cancer has changed the way in which many types of tumors
are treated (2). Despite good results in a minority of patients,
there is a major unmet clinical need for around 70% of the
patients receiving ICIs, who are refractory to this approach (3, 7).
For that reason, it is critical to improve our understanding of
how ICIs work and why they fail in many patients, to tailor
treatments that maximize the clinical outcome. In this regard,
virotherapy has been showing promising results in terms of
increasing the percentage of responders to ICIs (29, 31, 32).
Studying the interactions between ICIs and virotherapy in a
preclinical model is hampered by various limitations, which
probably explains the lack of work in this area, despite the
obvious importance of this area. For example, currently
available ICI refractory models are based on cell lines with
specific mutations, but these mutations are only rarely seen in
human patients (33). Ex vivo, models created out of patient-
derived samples are a valuable approach to study specific causes
for ICI resistance. However, it is currently not possible to have
a fully operational syngeneic immune system in humanized
mice models, since part of the tumor stroma – a key mediator
immune responses – derives from the mouse, causing species
incompatibility issues.July 2021 | Volume 12 | Article 706517
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competent mice (29) showed limited and heterogeneous
responses to aPD-1 when used as monotherapy. Although this
is somewhat surprising since both the cell line and mouse strain
are clonal, also others have reported the phenomenon of variable
response (30, 31). Mirroring reality in many human indications,
a fraction of mice shows limited responses, others show no
benefit, while a minority achieve complete responses. Inspired by
clinical guidelines relating to ICIs, we proposed a model that
considers tumors “refractory”, based on progression during
administration of the blocking antibody. In vivo determination
of the refractory status could have direct translatability into the
clinical arena. Furthermore, a widely used model for in vivoFrontiers in Immunology | www.frontiersin.org 7Oncoimmunology studies such as the B16.OVA model for C57
mice, offers reference frameworks in terms of survival to anti-
PD-1 (29, 34) and transcriptomic data (35, 36).
Anti-PD-1 refractory tumors displayed a significantly distinct
transcriptional profile when compared with similar tumors naïve
to aPD-1. Specifically, the gene-expression profile in these
tumors represented immunosuppressive characteristics. In
addition, the refractory status was validated in a different
experiment, where animals considered “refractory” to the ICI
showed no benefit, in terms of tumor growth control, after the
antibody was administered.
In this model, the mechanism behind the refractory nature
seems to support the hypothesis of resistance to therapy resultingA B
C
FIGURE 4 | Tumor samples and analysis to study mechanism of action of the treatments. (A) Experimental design: 27 mice carrying B16.OVA tumors were treated
with aPD-1 until they became refractory to the drug as described previously. Subsequently, those animals were assigned to groups where animals were treated with
the same aPD-1 regimen (n=9), with 1x108 VP intratumorally once every three days (n=9), or both (n= 9). Four rounds of treatments were given at days 0, 1, 3 and 6
after they were considered refractory and sacrificed at day 7 for tumor collection. (B) Average tumor volumes (and SEM) at day 0 (when they qualified as refractory)
and day 7 (when tumors were harvested). (C) Heatmap after the analysis of tumors by CyTOF and subsequent processing of the data by FLOWSOM providing 64
different cell clusters for immune (CD45+) cells. (Mann Whitney test; ***p < 0.001).July 2021 | Volume 12 | Article 706517
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particular, downregulated genes in refractory tumors correlate
lack of response to aPD-1 with reduced effector T-cell function.
Additionally, FOXP3, the main transcriptional factor for
regulatory T cells, was upregulated in refractory tumors. Other
upregulated genes in aPD-1 treated tumors might be remnants of
initial effect of aPD-1, like the upregulation of genes related to
complement system (37) or B-cells (38). The emergence of these
genes relates to the heterogeneous process through which tumors
move from immune equilibrium to escape during aPD-1 therapy.
The main purpose here was not to decipher the details that drive
aPD-1 resistance, but to study if such resistance could be overcome
or bypassed by the use of virotherapy. Therefore, aPD-1 refractory
tumors were treated with viruses coding for TNFa and IL-2. While
none of the aPD-1 refractory tumors showed signs of response to
aPD-1 as monotherapy, the inclusion of virotherapy (in addition to
aPD-1) triggered clear tumor growth control, and even some
complete responses.
Such complete responses are remarkable, as the challenge to
reject those tumors relates not only to the refractory status, but
also to high and rapidly increasing tumor volume. Tumor size
was around 8 times higher for the “rescue” treatment than for
initial ICI. Higher tumor volume results in a narrower window
for therapeutic success, because tumors are closer to the
maximum ethical volume allowed.
Interestingly, rather than exploiting a different mechanism of
action to drive anti-tumor responses bypassing aPD-1 resistance,
virotherapy is able to tackle the suppressive status of the tumor,
making them susceptible to PD-1 blockade. In this approach it isFrontiers in Immunology | www.frontiersin.org 8particularly relevant to take into consideration that the
virotherapy used in these experiment is engineered to express
TNFa and IL-2, two molecules that have shown notable ability to
induce T-cell activity (22). That hypothesis explains why
virotherapy together with aPD-1 renders better results than
virotherapy alone, even if the tumor is not intrinsically
susceptible to the antibody.
Another factor to take into account is the half-life of IgG2a
antibodies in mice. The suggested time for clearing half of the
antibody in adult mice is 6-8 days (39), which means that even
when virotherapy is administered as monotherapy, the mice will still
have some aPD-1 present in their serum. There is room to speculate
that if there would be absolutely no aPD-1 in those animals treated
with virotherapy only, the results in that group would be worse. The
situation would be similar in human individuals refractory to aPD-1.
The half-lives of pembrolizumab and nivolumab are 25 and 27 days,
respectively, meaning that some antibody is present for months after
the patient is determined refractory. Our results suggest that
continuing inhibition of the PD-1 axis can be useful for obtaining
maximum benefits of T-cell stimulating virotherapy. The
combination of drugs opens the door for increased incidence and
severity of adverse events. Other approaches including the
combination of two immune checkpoint inhibitors like anti-PD-1
and anti-CTLA-4 are an example of that phenomenon (40). In that
sense, the combination of two therapies with different mechanism of
action such as an oncolytic virus and a checkpoint inhibitor has been
reviewed as a safer approach (41). Another important dimension
when comparing the benefits and risks of the treatments is the length






FIGURE 5 | Changes in key immune populations after virotherapy assessed by mass cytometry and cluster analysis. Unbiased cell cluster generation from CD45+
fraction rendered multiple clusters that were associated to a cell type or phenotype. Relative percentage of those clusters among experimental groups were compared
using Mann-Whitney test (average value and SEM included). Key markers to identify the cluster identity are indicated. (A) cluster 25. (B) cluster 41. (C) cluster 10.
(D) cluster 17. (E) cluster 6. (F) cluster 14. (G) cluster 36. (H) cluster 5. (I) cluster 39. (J) cluster 58. (K) cluster 32. (L) cluster 55. *p < 0.05; ***p < 0.001.July 2021 | Volume 12 | Article 706517
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the preferred approach when using them is to dose until complete
response, clear tumor progression or occurrence of severe adverse
events. In line with those clinical observations, animals included in
this study were daily monitored by trained veterinarians and the
approach was reported safe.
Focusing on the changes observed in the immune
compartment after virotherapy was administered to aPD-1
refractory tumors, the main readout seems to be that the
treatment increased frequencies of multiple CD8 T-cell
subpopulations in the tumor, covering different developmental
and functional stages. The data obtained after mass cytometry
analysis of the tumor samples matches the previously proposed
hypothesis on human tumors becoming refractory due to T-cell
absence or dysfunction (43, 44). Virotherapy could counter the
changes in CD8 cells that are making the tumors resistant to
aPD-1. Upregulation of CD8 clusters with activation (CD69) and
proliferation (Ki-67) markers, but low levels of exhaustion
markers (TIM-3 and CTLA-4 double positives) supporting the
hypothesis of an increased presence of functional antitumor
adaptive responses. Many of these immune checkpoint
pathways have a double nature, in the sense that they can be
understood as an activation marker (as they upregulate after the
T cell is activated) but also they are a source of inhibition when
bound to their ligand(s), in that sense when the expression of
TIM-3 and CTLA-4 was not coupled to activation and
proliferation markers, it was classified of a signal of exhaustion.
PD-1 expression on T cells is a relevant marker in this set-up as that
molecule is the target of the checkpoint inhibitor used in this study.
In that sense, cluster 3 is the subset of CD8 T cells with higher PD-1
but it is not differentially expressed in any of the testing groups.
Perhaps, the initial aPD-1 treatment received by every animal to
make them resistant to the antibody, normalizes the expression
among all of them and that effect is not changes after
subsequent treatments.
Additional understanding on the functional and phenotypical
features of tumor infi ltrating T cells could provide
complementary insights to the impact of the therapies into this
cell population. In particular, intracellular staining for different
effector cytokines and transcription factors could help to
determine which specific T-cell subsets are induced. Typically
cytotoxic cells (sometimes called Tc1 subtype) are efficient in
killing tumor and pathogen-harboring cells and they have
associated markers such as intracellular IFN gamma and TNFa
as well as transcription factors like EOMES, T-bet and STAT-4,
while other T-cell subsets, like the Tc17 with low cytotoxic
activity (45). Similarly, more in-depth characterization of T-
cells would be beneficial, for example, the addition of CD45RA
and CCR7 would help in terms of delineation of specific effector/
memory subtypes (terminal effector memory, central memory or
effector memory).
Adenovirus-induced changes in T-cell populations appear to
be specific to CD8 subsets, as no significant changes were
observed in conventional CD4 T cell clusters, or the regulatory
CD4 T cell cluster. The fact that the active CD8 to Treg ratio isFrontiers in Immunology | www.frontiersin.org 9upregulated with the double treatment also points to a general
environment repolarization. In addition, other cell populations
suggested as candidates to mediate ICI resistance, such as
MDSCs (46, 47) and M2 macrophages (7, 48) were
significantly downregulated after virotherapy treatments.
Regarding dendritic cells, it is remarkable to see how the
presence of the viruses did not increase their presence in the
tumor even if they include recognizable danger-associated
molecular patterns (49). Perhaps the counterintuitive results
regarding the dendritic cell compartment are related to the
non-replicative nature of the virus in the model. Even if the T-
cell compartment seems to be key in this model of aPD-1
resistance, it would be interesting to investigate the role of
other cell types such as B cells or NK cells as well. For
example, Xiao X (50) et al. identified a B cell population with
high PD-1 expression and T-cell regulatory functions that could
be relevant in the context of PD-1 blockade resistance.
We previously showed how the contribution of the cytokines
encoded in the viruses is critical in engaging strong antitumor
immune responses (23, 24). In that sense, the work described by
Vredevoogd D et al (51) is specifically relevant. They showed
how TNFa-related signaling could be exploited to trigger
immune responses in tumors with defective responses to IFN
signals. In that study, reducing the threshold for TNFa signals in
the tumor caused effective immune rejection of tumors. In the
present work, the presence of an immunogenic agent, such as the
adenovirus, together with an increased concentration of
transgenic TNFa at the tumor niche, could have a similar effect
in overcoming immune resistance. When studied the impact of
this virotherapeutic approach on metastases (52) and uninjected
lesions (53) used in a replication competent model, it was seen
how the antitumor efficacy and tumor microenvironment re-
shaping also extends to those disseminated lesions. All in all, the
use of this virotherapy has previously proved to be a valid
approach to engage systemic antitumor responses which
synergize with the systemically administered ICIs.
The work described herein focuses on studying how to
increase responses of aPD-1 refractory tumors. For that
purpose, a unique in vivo model was established and validated
in the matter of resistance to the inhibitory antibody. In this
model, tumors that escaped after aPD-1 administration showed a
significant downregulation of immune activities mainly related
with the T-cell compartment. The addition of TNFa and IL-2
armed adenoviruses to the aPD-1 regimen managed to revert the
previously established resistance to aPD-1 by increasing the
presence of different CD8 T cell subsets that can mediate
antitumor immunity. In addition, reduced frequencies of
suppressive cells (M2 macrophages and MDSCs) likely
contributed to increased survival after the administration of
virotherapy to aPD-1 refractory tumors. The biological
mechanisms uncovered here support the continuation of ICI
together with TNFa and IL-2 virotherapy, even if the tumor was
originally resistant to the antibody. These preclinical results have
been translated into a clinical protocol where anti-PD-(L)1
refractory tumors will be treated with TILT-123 and avelumab.July 2021 | Volume 12 | Article 706517
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